Antioxidants, diabetes and endothelial dysfunction

Cardiovascular Research

Volumn 47, Issue 3, 2000, Pages 457-464

  Laight, D W ^a   Carrier, M J ^a   Anggard E E ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Blood flow; Diabetes; Endothelial function; Free radicals; Nitric oxide

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FREE RADICAL; INSULIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

BLOOD FLOW; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE UTILIZATION; HORMONE ACTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS; VASCULAR ENDOTHELIUM; VASODILATATION; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MODELS, BIOLOGICAL; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REGIONAL BLOOD FLOW; VASODILATION;

EID: 0034683051     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00054-7     Document Type: Review

References (123)

1. Reaven G.M. Role of insulin resistance in human disease. Physiol Rev. 75:1995;473-486.
2. Chisholm D.J., Campbell L.V., Kraegen E.W. Pathogenesis of the insulin resistance syndrome (syndrome X). Clin Exp Pharmacol Physiol. 24:1997;782-784.
3. McCarty M.F. Haemostatic concomitants of syndrome X. Med Hypotheses. 44:1994;179-193.
4. Stamler J., Vaccaro O., Neaton J.D., et al. The multiple risk factor intervention trial research group: diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 16:1993;434-444.
5. Tooke J.E., Shore A.C., Cohen R.A., et al. Diabetic angiopathy: tracking down the culprits. J Diabetes Complications. 10:1996;173-181.
6. Vanhoutte P.M. Endothelial dysfunction and atherosclerosis. Eur Heart J. 18:1997;E19-E29.
7. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:1990;801-809.
8. Hsueh W.A., Quinones M.J., Creager M.A. Endothelium in insulin resistance and diabetes. Diebetes Rev. 5:1997;343-352.
9. Stehouwer C.D.A., Lambert J., Donker A.J.M., et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 34:1997;55-68.
10. Pinkney J.H., Coen D.A., Stehouwer C.D.A., et al. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 16:1997;S9-S13.
11. Tooke J.E., Goh K.L. Endotheliopathy precedes type 2 diabetes. Diabetes Care. 21:1998;2047-2048.
12. Laight D.W., Carrier M.J., Änggård E.E. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev. 15:1999;274-282.
13. Steinberg H.O., Brechtel G., Johnson A., et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. J Clin Invest. 94:1994;1172-1179.
14. Scherrer U., Randin D., Vollenweider P., et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 94:1994;2511-2515.
15. Taddei S., Virdis A., Mattei P., et al. Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation. 92:1995;147-152.
16. Laight D.W., Kaw A.V., Carrier M.J., et al. Pharmacological modulation of endothelial function by insulin in the rat aorta. J Pharm Pharmacol. 50:1998;1117-1120.
17. Laakso M., Edelam S.V., Brechtel G., et al. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1992;1076-1083.
18. Steinberg H.O., Chaker H., Leaming R., et al. Obesity/insulin resistance is associated with endothelial dysfunction. J Clin Invest. 97:1996;2601-2610.
19. Shoemaker J.K., Bonen A. Vascular actions of insulin in health and disease. Can J App Physiol. 20:1995;127-154.
20. Tack C.J., Ong M.K., Lutterman J.A., et al. Insulin-induced vasodilation and endothelial function in obesity/insulin resistance. Effects of troglitazone. Diabetologia. 41:1998;569-576.
21. Vischer U.M. Insulin resistance and the regulation of vascular tone: is insulin a vasodilator? Eur J Endocrinol. 138:1998;262-263.
22. Walker A.B., Dores J., Buckingham R.E., et al. Impaired insulin induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin Sci. 93:1997;235-241.
23. Lembo G., Morella A., Lanni F., et al. Vascular insulin resistance in hypertension. Nutr Metab Cardiovasc Dis. 7:1997;124-126.
24. Panza J.A., Casino P.R., Kilcoyne C.M., et al. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 87:1993;1468-1474.
25. Perfetto F., Tarquini R., de Leonardis V., et al. Angiopathy affects circulating endothelin-1 levels in type 2 diabetic patients. Acta Diabetol. 32:1995;263-267.
26. Sarman B., Toth M., Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev. 14:1998;171-175.
27. Velasquez M.T., Bhathena S.J., Striffler J.S., et al. Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism. 47:1998;7-11.
28. Anderson S. Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab. 24:1998;406-411.
29. Giugliano D., Marfella R., Acampora R., et al. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care. 21:1998;631-636.
30. O'Driscoll G., Green D., Maiorana A., et al. Improvement in endothelial function by angiotensin-converting enzyme inhibition in NIDDM. J Am Coll Cardiol. 33:1999;1506-1511.
31. Ganrot P.O. Insulin resistance syndrome: possible key role of blood flow in resting muscle. Diabtologia. 36:1993;876-879.
32. McVeigh G.E., Brennan G.M., Johnston G.D., et al. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 35:1992;771-776.
33. Hogikyan R.V., Halter J.B., Galecki A.T., et al. Specific impairment of endothelium-dependent vasodilation in subjects with type II diabetes independent of obesity. J Clin Endocrinol Metab. 83:1998;1946-1952.
34. Mohan I.K., Das U.N. Oxidant stress, antioxidants and nitric oxide in non-insulin dependent diabetes mellitus. Med Sci Res. 25:1997;55-57.
35. Wiernsperger N. Vascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypotheses and facts. Diabetes Metab Rev. 10:1994;287-307.
36. Baron A.D., Steinberg H.O., Chaker H., et al. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 96:1995;779-786.
37. Baron A.D. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide. Diabetes. 45:1996;S105-S109.
38. Petrie J.R., Ueda S., Webb D.J., et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with importance for pathogenesis of cardiovascular disease. Circulation. 93:1996;1331-1333.
39. Avogaro A., Piarulli F., Valerio A., et al. Forearm nitric oxide balance, vascular relaxation and glucose metabolism in NIDDM patients. Diabetes. 46:1997;1040-1046.
40. Utriainen T., Mäkimattila S., Virkamaki A., et al. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia. 39:1996;1477-1482.
41. Baron A.D., Laakso M., Brechtel G., et al. Mechanism of insulin resistance in IDDM: a major role for reduced skeletal muscle blood flow. J Clin Endocrinol Metab. 73:1991;637-643.
42. Summers L.K.M., Samra J.S., Frayn K.N. Impaired postprandial tissue regulation of blood flow in insulin resistance: a determinant of cardiovascular risk? Atherosclerosis. 147:1999;11-15.
43. Miles P.D.G., Li S., Hart M., et al. Mechanism of insulin resistance in experimental hyperinsulinaemic dogs. J Clin Invest. 101:1998;202-211.
44. Castillo C., Bogardus C., Bergman R., et al. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J Clin Invest. 93:1994;10-16.
45. Miles P.D.G., Levisetti M., Reichart D., et al. Kinetics of insulin action in vivo: identification of rate limiting steps. Diabetes. 44:1995;947-953.
46. Lillioja S., Young A.A., Culter C.L., et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 80:1987;415-424.
47. Wascher T.C. Endothelial transport processes and tissue metabolism: evidence for microvascular endothelial dysfunction in insulin-resistant diseases? Eur J Clin Invest. 27:1997;831-835.
48. Natali A. Skeletal muscle blood flow and insulin action. Nutr Metab Cardiovasc Dis. 7:1997;105-109.
49. Laine H., Yki-Jarvinen H., Kirvela O., et al. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity. J Clin Invest. 101:1998;1156-1162.
50. Bloomgarden Z.T. Insulin resistance: current concepts. Clin Ther. 20:1998;216-231.
51. Wolff S.P. Diabetes mellitus and free radicals. Br Med Bull. 49:1993;642-652.
52. 2α levels are elevated in individuals with NIDDM. FEBS Lett. 368:1995;225-229.
53. Laight D.W., Kengatharan K.M., Gopaul N.K., et al. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br J Pharmacol. 125:1998;895-901.
54. Ceriello A., Bortolotti N., Crescentini A., et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest. 28:1998;329-333.
55. Giugliano D., Paolisso G., Ceriello A. Oxidative stress and diabetic vascular complications. Diabetes Care. 19:1996;257-267.
56. Taniguchi N.H., Asahi M., Takahashi M., et al. Involvement of glycation and oxidative stress in diabetic macroangiopathy. Diabetes. 45:1996;S81-S83.
57. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med. 16:1993;383-391.
58. Bult H. Nitric oxide and atherosclerosis: possible implications for therapy. Mol Med Today. 2:1996;510-518.
59. Pritchard K.A.J., Groszek L., Smalley D.M., et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 77:1994;354-357.
60. Paolisso G., D'Amore A., Volpe C., et al. Evidence for a relationship between oxidative stress and insulin action in NIDDM patients. Metabolism. 43:1994;1426-1429.
61. 2-isoprostane evidence of oxidant stress in the insulin resistant obese Zucker rat: effects of vitamin E. Eur J Pharmacol. 377:1999;89-92.
62. Laight D.W., Desai K.M., Gopaul N.K., et al. Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br J Pharmacol. 128:1999;269-271.
63. Bertelsen M., Andersson M.B., Änggård E.E., et al. Role of reactive oxygen species on tans-endothelial insulin transport. Br J Pharmacol. 125:1998;P120.
64. Gryglewski R.J., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature. 329:1986;454-458.
65. Darley-Usmar V., White R. Disruption of vascular signalling by the reaction of nitric oxide with superoxide: implications for cardiovascular disease. Exp Physiol. 82:1997;305-316.
66. Laight D.W., Kaw A.V., Carrier M.J., et al. Interaction between superoxide anion and nitric oxide in the regulation of vascular endothelial function. Br J Pharmacol. 124:1998;238-244.
67. Ting H.H., Timimi F.K., Boles K.S., et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 97:1996;22-28.
68. Levine G.N., Frei B., Koulouris S.N., et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 93:1996;1107-1113.
69. Mäkimattila S., Liu M.-L., Vakkilainen J., et al. Impaired endothelium-dependent vasodilation in type 2 diabetes. Diabetes Care. 22:1999;973-981.
70. Anderson J.W., Gowri M.S., Turner J., et al. Antioxidant supplementation effects on low density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr. 18:1999;451-461.
71. Verges B.L. Dyslipidaemia in diabetes mellitus. Diabetes Metab. 25:1999;32-40.
72. Witztum J.L. The oxidation hypothesis of atherosclerosis. Lancet. 344:1994;793-795.
73. Pieper G.M., Gross G.J. Oxygen free radicals abolish endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol. 255:1988;H825-H833.
74. Langenstroer P., Peiper G.M. Regulation of spontaneous EDRF release in diabetic rat aorta by oxygen free radicals. Am J Physiol. 263:1992;H257-H265.
75. Diederich D., Skopec J., Diederich A., et al. Endothelial dysfunction in mesenteric resistance arteries of diabetic rats: role of free radicals. Am J Physiol. 266:1994;H1153-H1161.
76. Hattori Y., Kawasaki H., Abe K., et al. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol. 261:1991;H1086-H1094.
77. Keegan A., Walbank H., Cotter M.A., et al. Chronic vitamin E treatment prevents defective endothelium-dependent relaxation in diabetic rat aorta. Diabetologia. 38:1995;1475-1478.
78. Rosen P., Ballhausen T., Bloch W., et al. Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as antioxidant. Diabetologia. 38:1995;1157-1168.
79. Dai F.-X., Diederich A., Skopec J., et al. Diabetes-induced endothelial dysfunction in STZ-treated rats: role of prostaglandin endoperoxides and free radicals. J Am Soc Nephrol. 4:1993;1327-1336.
80. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med. 16:1993;383-391.
81. Ralevic V., Milla P.J., Burnstock G. Effects of chronic vitamin E deficiency on vascular function - a study of sympathetic nerves, smooth muscle and endothelium of the mesenteric arterial bed of the rat. Br J Pharmacol. 116:1995;2983-2988.
82. Davidge S.T., Ojimba J., McLaughlin M.K. Vascular function in the vitamin E-deprived rat. Hypertension. 31:1998;830-835.
83. Timimi F.K., Ting H.H., Haley M., et al. Vitamin C improves endothelium-dependent vasodilation in IDDM. J Am Coll Nephrol. 31:1998;552-557.
84. Duffy S.J., Gokce N., Holbrook M., et al. Treatment of hypertension with ascorbic acid. Lancet. 354:1999;2048-2049.
85. Heller R., Münscher-Paulig F., Gräbner R., et al. L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem. 274:1999;8254-8260.
86. Honing M.J.H., Morrison P.J., Banga J.D., et al. Nitric oxide availability in diabetes mellitus. Diabetes Metab Rev. 14:1998;241-249.
87. Giugliano D., Paolisso G., Coppla L. Hyperglycaemia and endothelial dysfunction in human diabetes: does oxidative stress play a role? Nutr Metab Cardiovasc Dis. 7:1997;100-104.
88. Sobrevia L., Mann G.E. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Phyisol. 82:1997;423-452.
89. Ono H., Umeda F., Inoguchi T., et al. Glucose inhibits prostacyclin production by cultured aortic endothelial cells. Thromb Haemost. 60:1988;174-177.
90. Tesfamariam B., Brown M.L., Deykin D., et al. Elevated glucose promotes generation of endothelium-derived vasoconstrictor prostanoids in rabbit aorta. J Clin Invest. 85:1990;929-932.
91. Yamaguchi T., Ohnaka K., Takayanagi R., et al. Enhanced secretion of endothelin 1 by elevated glucose levels from cultured endothelial cells. FEBS Lett. 267:1990;16-18.
92. Falkenhahn M., Gohlke P., Paul M., et al. The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects. J Cardiovasc Pharmacol. 24:1994;S6-S13.
93. Schalekamp M.A.D.H. Renin-angiotensin system components and endothelial proteins as markers of diabetic microvascular disease. Clin Invest. 71:1993;S3-S6.
94. Hsueh W.A., Anderson P.W. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiol. 72:1993;14H-21H.
95. Kleinert S. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Lancet. 354:1999;841.
96. Jaap A.J., Tooke J.E. Pathophysiology of microvascular disease in NIDDM. Clin Sci. 89:1995;3-12.
97. Graier W.F., Posch K., Wascher T.C. Role of superoxide anions in changes of endothelial vasoactive response during acute hyperglycaemia. Horm Metab Res. 29:1997;622-626.
98. 2+/cGMP response by scavenging superoxide anions. Eur J Pharmacol. 322:1997;113-122.
99. Kanner J., Harel S., Granit R. Nitric oxide as an antioxidant. Arch Biochem Biophys. 289:1991;130-136.
100. Halliwell B. Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic Res. 25:1996;57-74.
101. Hogg N., Kalyanaraman B. Nitric oxide and lipid peroxidation. Biochim Biophys Acta. 1411:1999;378-384.
102. Laight D.W., Kaw A.V., Carrier M.J., et al. Interaction between superoxide anion and nitric oxide in the regulation of vascular endothelial function. Br J Pharmacol. 124:1998;238-244.
103. Ceriello A., Bortolotti N., Falleti E., et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care. 20:1997;194-197.
104. Ceriello A., Bortolotti N., Pirisi M., et al. Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care. 20:1997;1589-1593.
105. Aguirre F., Martin I., Grinspon D., et al. Oxidative damage, plasma antioxidant capacity and glycaemic control in elderly patients. Free Radic Biol Med. 24:1998;580-585.
106. Haffner S.M., Agil A., Mykkanen L., et al. Plasma oxidisability in subjects with normal glucose tolerance, impaired glucose tolerance and NIDDM. Diabetes Care. 18:1995;646-653.
107. Maxwell S.R.J., Thomason H., Sandler D., et al. Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in NIDDM. Ann Clin Biochem. 34:1997;638-644.
108. Paolisso G., D'Amore A., Balbi V., et al. Plasma vitamin C affects glucose homeostasis in healthy subjects and in NIDDM. Am J Physiol. 266:1994;E261-E268.
109. Ashour M., Salem S., Hassaneen H., et al. Antioxidant status and IDDM. J Clin Biochem Nutr. 26:1999;99-107.
110. Tüzün S., Girgin F.K., Sözmen E.Y., et al. Antioxidant status in experimental type 2 diabetes mellitus: effects of glibenclamide and glipizide on various rat tissues. Exp Toxicol Pathol. 51:1999;436-441.
111. Vendemiale G., Grattagliano I., Altomare E. An update on the role of free radicals an diabetes antioxidant defense in human disease. Int J Clin Lab Res. 29:1999;49-55.
112. Patel M., Day B.J. Metalloporphyrin class of therapeutic catalytic antioxidants. Trends Pharmacol Sci. 20:1999;359-364.
113. Nuttall S.L., Kendall M.J., Martin U. Antioxidant therapy for the prevention of cardiovascular disease. Q J Med. 92:1999;239-244.
114. Maxwell S.R.J. Prospects for the use of antioxidant therapies. Drugs. 49:1995;345-361.
115. Palace V.P., Khaper N., Qin Q., et al. Antioxidant potentials of vitamin A and carotenoids and their relevance to heart disease. Free Radic Biol Med. 26:1999;746-761.
116. Kendall M.J., Nuttall S.L., Martin U. Antioxidant therapy - a new therapeutic option for reducing mortality from coronary artery disease. J Clin Pharm Ther. 23:1998;323-325.
117. Gaziano J.M. Antioxidant vitamins and cardiovascular disease. Proc Assoc Am Phys. 111:1999;2-9.
118. Ford E.S., Will J.C., Bowman B.A., et al. Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Survey. Amount J Epidemiol. 149:1999;168-176.
119. Marchioli R. Antioxidant vitamins and prevention of cardiovascular disease: laboratory, epidemiological and clinical trial data. Pharmacol Res. 40:1999;227-238.
120. Jain S.K., McVie R., Jaramillo J.J., et al. The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids. 31:1996;S87-S90.
121. Maxwell S.R.J. Antioxidant vitamin supplements. Drug Safety. 21:1999;253-266.
122. Bellomo G. Is it really time to perform large intervention trials with antioxidant vitamins to prevent cardiovascular disease? Pharmacol Res. 40:1999;207-208.
123. Stern M.P. Do NIDDM and cardiovascular disease share common antecedents? Ann Intern Med. 124:1996;110-116.